Register Login

Antiplatelet Therapy

A Molecular Approach to Assess Platelet Hyperreactivity

Friend Ed Groenendal forwarded this UPI summary of a molecular approach correlating evidence of hyperresponsive platelets to major adverse cardiac or limb events. The investigators started with aggregometry-defined platelet hyperreactivity to apply a transcriptome-based platelet reactivity expression score (PRESS). Click below to see the detailed open-access article describing the development and application of the PRESS. […]
read more

Primary CVD Disease: Is Low Dose ASA Effective?

Thanks to Dean Willett, Precision BioLogic Inc, for pointing me to this October 12, 2021 US Preventive Services Task Force release, “Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication,” which recommends against daily low-dose aspirin as a means to reduce the risk of cardiovascular disease, ischemic stroke, and colorectal cancer regardless of age or comorbities. […]
read more

Zontivity (vorapaxar)

I’m curious about how many of our participants monitor vorapaxar (Zontivity®, New American Therapeutics, Inc) antiplatelet therapy. Vorapaxar is the only protease-activated receptor-1 (PAR-1) antagonist that reduces thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease, FDA-approved in 2014. Vorapaxar is used alongside dual antiplatelet therapy (aspirin and clopidogrel; aspirin and ticagrelor) […]
read more